Zacks: Analysts Expect Strongbridge Biopharma PLC (SBBP) to Announce -$0.41 EPS

Wall Street brokerages predict that Strongbridge Biopharma PLC (NASDAQ:SBBP) will announce earnings per share of ($0.41) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Strongbridge Biopharma PLC’s earnings, with the highest EPS estimate coming in at ($0.37) and the lowest estimate coming in at ($0.48). Strongbridge Biopharma PLC reported earnings per share of ($0.36) during the same quarter last year, which suggests a negative year over year growth rate of 13.9%. The firm is scheduled to issue its next earnings report on Friday, December 22nd.

On average, analysts expect that Strongbridge Biopharma PLC will report full year earnings of ($2.66) per share for the current year. For the next financial year, analysts forecast that the business will report earnings of ($1.30) per share, with EPS estimates ranging from ($1.65) to ($1.01). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Strongbridge Biopharma PLC.

Strongbridge Biopharma PLC (NASDAQ:SBBP) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.34) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.34). The company had revenue of $1.53 million during the quarter, compared to analyst estimates of $0.84 million.

SBBP has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a research note on Thursday, September 28th. ValuEngine downgraded shares of Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Finally, Oppenheimer Holdings, Inc. initiated coverage on shares of Strongbridge Biopharma PLC in a research note on Thursday, August 10th. They set an “outperform” rating and a $12.00 price target on the stock. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. Strongbridge Biopharma PLC has an average rating of “Hold” and a consensus target price of $11.94.

Strongbridge Biopharma PLC (SBBP) remained flat at $6.15 during mid-day trading on Wednesday. 69,307 shares of the company were exchanged. The company’s 50-day moving average is $6.79 and its 200-day moving average is $5.70. Strongbridge Biopharma PLC has a 52 week low of $2.00 and a 52 week high of $8.85. The firm’s market capitalization is $217.31 million.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect Strongbridge Biopharma PLC (SBBP) to Announce -$0.41 EPS” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.chaffeybreeze.com/2017/10/07/zacks-analysts-expect-strongbridge-biopharma-plc-sbbp-to-announce-0-41-eps.html.

Several institutional investors have recently added to or reduced their stakes in the company. Broadfin Capital LLC increased its position in shares of Strongbridge Biopharma PLC by 3.0% in the first quarter. Broadfin Capital LLC now owns 2,981,706 shares of the biotechnology company’s stock worth $14,163,000 after acquiring an additional 87,125 shares in the last quarter. Northern Trust Corp acquired a new stake in shares of Strongbridge Biopharma PLC in the second quarter worth $1,462,000. Nexthera Capital LP acquired a new stake in shares of Strongbridge Biopharma PLC in the second quarter worth $477,000. Vanguard Group Inc. acquired a new stake in shares of Strongbridge Biopharma PLC in the second quarter worth $474,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in shares of Strongbridge Biopharma PLC in the second quarter worth $449,000. 63.65% of the stock is owned by institutional investors.

About Strongbridge Biopharma PLC

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Get a free copy of the Zacks research report on Strongbridge Biopharma PLC (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply